Dr. St.Clair, an academic rheumatologist, is strongly committed to a career in patient-oriented research. His clinical research program has focused on the pathogenesis and treatment of rheumatoid arthritis (RA). It has been highly productive within an integrative environment of outstanding clinical investigators, biostatisticians, and basic scientists. A Midcareer Investigator Award would enable Dr. St.Clair to obtain sufficient protected time to expand his successful clinical research program, seize new research opportunities, and build an effective mentoring system that would create a lasting enterprise for future investigators at Duke. Dr. St.Clair has been an active and independent clinical investigator. His current research has centered in part on the role of nitric oxide (NO) as a mediator of joint inflammation. These studies have been performed in collaboration with Dr. J. Brice Weinberg and supported by the Specialized Center for Research in RA. It is funded by the National Institutes of Health (NIH) and continues to yield a wealth of new research ideas and clinical projects. Dr. St.Clair and his coworkers have also just completed an NIH-funded pilot clinical trial of intravenous (i.v.) doxycycline therapy in RA. These data are currently being analyzed and will determine if this i.v. antibiotic regimen has potential clinical benefits in RA and will elucidate possible mechanisms of action. In addition, Dr. St.Clair has been an investigator in several multicenter clinical trials of novel biologics in RA, such as IL-10 and a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, and shown how patient specimens from these trials can be utilized to gain further insights into the biologic effects of cytokine manipulation. Duke University has built an enriching educational environment where Dr. St.Clair can establish an outstanding mentoring program. The centerpiece of the institutional environment is the Clinical Research Training Program. Other resources available to Dr. St.Clair and his trainees include the Department of Medicine Biostatistics Unit, the Duke Clinical Research Institute, and the Center for Health Services Research in Primary Care. The combined talents of many successful investigators at Duke and the availability of these critical resources provide Dr. St.Clair with outstanding clinical research opportunities and educational experiences for his trainees.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AR002126-02
Application #
6171483
Study Section
Special Emphasis Panel (ZAR1-JRL-C (M1))
Program Officer
Serrate-Sztein, Susana
Project Start
1999-09-15
Project End
2004-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
2
Fiscal Year
2000
Total Cost
$108,743
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Tomasson, Gunnar; Davis, John C; Hoffman, Gary S et al. (2014) Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's). Arthritis Rheumatol 66:428-32
Tomasson, Gunnar; Boers, Maarten; Walsh, Michael et al. (2012) Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 64:273-9
Tomasson, Gunnar; Lavalley, Michael; Tanriverdi, Kahraman et al. (2011) Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol 38:1048-54
Suppiah, Ravi; Judge, Andrew; Batra, Rajbir et al. (2011) A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 63:588-96
Finkielman, J D; Merkel, P A; Schroeder, D et al. (2009) Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clin Exp Rheumatol 27:S45-52
Finkielman, Javier D; Lee, Augustine S; Hummel, Amber M et al. (2007) ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 120:643.e9-14
Finkielman, Javier D; Merkel, Peter A; Schroeder, Darrell et al. (2007) Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147:611-9
Sebastian, Jodi K; Voetsch, Barbara; Stone, John H et al. (2007) The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 34:2446-50
Sebastian, Jodi K; Mahr, Alfred D; Ahmed, Sohail S et al. (2007) Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. J Rheumatol 34:1027-31
Stone, John H; Holbrook, Janet T; Marriott, Matthew A et al. (2006) Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54:1608-18